Nexstim Financial Statement Release 2016
Helsinki, 28 February 2017 at 9:00 am
Company Highlights, July – December 2016
? Nexstim agreed a long-term financing arrangements in the form of a joint deal with Bracknor Investment and Sitra resulting in EUR 8.5 million in cash
? Nexstim received US Food and Drug Administration's (FDA) approval to commence the E-FIT trial
? NBS revenues EUR 1.6 million (2015: EUR 1.9 million)
? Key technology patent granted in EU adding further global validation of pioneering fully integrated NBS and NBT® technology
Post period end highlight
For full access, please click here.
Company Highlights, July – December 2016
? Nexstim agreed a long-term financing arrangements in the form of a joint deal with Bracknor Investment and Sitra resulting in EUR 8.5 million in cash
? Nexstim received US Food and Drug Administration's (FDA) approval to commence the E-FIT trial
? NBS revenues EUR 1.6 million (2015: EUR 1.9 million)
? Key technology patent granted in EU adding further global validation of pioneering fully integrated NBS and NBT® technology
Post period end highlight
For full access, please click here.